

Pulmonary Hypertension-EMEA Market Status and Trend Report 2013-2023

| | |
|--------|---|
| URL: | https://marketpublishers.com/r/P5E0F7B9BF28EN.html |
| Date: | May 21, 2018 |
| Pages: | 138 |
| Price: | US\$ 3,480.00 |
| ID: | P5E0F7B9BF28EN |

Report Summary

Pulmonary Hypertension-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Pulmonary Hypertension industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Pulmonary Hypertension 2013-2017, and development forecast 2018-2023

Main market players of Pulmonary Hypertension in EMEA, with company and product introduction, position in the Pulmonary Hypertension market

Market status and development trend of Pulmonary Hypertension by types and applications

Cost and profit status of Pulmonary Hypertension, and marketing status

Market growth drivers and challenges

The report segments the EMEA Pulmonary Hypertension market as:

EMEA Pulmonary Hypertension Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Pulmonary Hypertension Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Prostacyclin and prostacyclin analogs

Endothelin receptor antagonists (ERAs)

Phosphodiesterase-5 (PDE-5) inhibitors

Soluble guanylate cyclase (sGC) stimulators

EMEA Pulmonary Hypertension Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Pulmonary Arterial Hypertension (PAH)

EMEA Pulmonary Hypertension Market: Players Segment Analysis (Company and Product introduction, Pulmonary Hypertension Sales Volume, Revenue, Price and Gross Margin):

Bayer

GSK

Arena

Actelion

Pfizer
United Therapeutics
Gilead Sciences
Lung Biotechnology PBC

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Table of Content

CHAPTER 1 OVERVIEW OF PULMONARY HYPERTENSION

- 1.1 Definition of Pulmonary Hypertension in This Report
- 1.2 Commercial Types of Pulmonary Hypertension
 - 1.2.1 Prostacyclin and prostacyclin analogs
 - 1.2.2 Endothelin receptor antagonists (ERAs)
 - 1.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
 - 1.2.4 Soluble guanylate cyclase (sGC) stimulators
- 1.3 Downstream Application of Pulmonary Hypertension
 - 1.3.1 Pulmonary Arterial Hypertension (PAH)
- 1.4 Development History of Pulmonary Hypertension
- 1.5 Market Status and Trend of Pulmonary Hypertension 2013-2023
 - 1.5.1 EMEA Pulmonary Hypertension Market Status and Trend 2013-2023
 - 1.5.2 Regional Pulmonary Hypertension Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Pulmonary Hypertension in EMEA 2013-2017
- 2.2 Consumption Market of Pulmonary Hypertension in EMEA by Regions
 - 2.2.1 Consumption Volume of Pulmonary Hypertension in EMEA by Regions
 - 2.2.2 Revenue of Pulmonary Hypertension in EMEA by Regions
- 2.3 Market Analysis of Pulmonary Hypertension in EMEA by Regions
 - 2.3.1 Market Analysis of Pulmonary Hypertension in Europe 2013-2017
 - 2.3.2 Market Analysis of Pulmonary Hypertension in Middle East 2013-2017
 - 2.3.3 Market Analysis of Pulmonary Hypertension in Africa 2013-2017
- 2.4 Market Development Forecast of Pulmonary Hypertension in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Pulmonary Hypertension in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Pulmonary Hypertension by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
 - 3.1.1 Consumption Volume of Pulmonary Hypertension in EMEA by Types
 - 3.1.2 Revenue of Pulmonary Hypertension in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East
 - 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Pulmonary Hypertension in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Pulmonary Hypertension in EMEA by Downstream Industry
- 4.2 Demand Volume of Pulmonary Hypertension by Downstream Industry in Major Countries

- 4.2.1 Demand Volume of Pulmonary Hypertension by Downstream Industry in Europe
- 4.2.2 Demand Volume of Pulmonary Hypertension by Downstream Industry in Middle East
- 4.2.3 Demand Volume of Pulmonary Hypertension by Downstream Industry in Africa
- 4.3 Market Forecast of Pulmonary Hypertension in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PULMONARY HYPERTENSION

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Pulmonary Hypertension Downstream Industry Situation and Trend Overview

CHAPTER 6 PULMONARY HYPERTENSION MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Pulmonary Hypertension in EMEA by Major Players
- 6.2 Revenue of Pulmonary Hypertension in EMEA by Major Players
- 6.3 Basic Information of Pulmonary Hypertension by Major Players
 - 6.3.1 Headquarters Location and Established Time of Pulmonary Hypertension Major Players
 - 6.3.2 Employees and Revenue Level of Pulmonary Hypertension Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 PULMONARY HYPERTENSION MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Bayer
 - 7.1.1 Company profile
 - 7.1.2 Representative Pulmonary Hypertension Product
 - 7.1.3 Pulmonary Hypertension Sales, Revenue, Price and Gross Margin of Bayer
- 7.2 GSK
 - 7.2.1 Company profile
 - 7.2.2 Representative Pulmonary Hypertension Product
 - 7.2.3 Pulmonary Hypertension Sales, Revenue, Price and Gross Margin of GSK
- 7.3 Arena
 - 7.3.1 Company profile
 - 7.3.2 Representative Pulmonary Hypertension Product
 - 7.3.3 Pulmonary Hypertension Sales, Revenue, Price and Gross Margin of Arena
- 7.4 Actelion
 - 7.4.1 Company profile
 - 7.4.2 Representative Pulmonary Hypertension Product
 - 7.4.3 Pulmonary Hypertension Sales, Revenue, Price and Gross Margin of Actelion
- 7.5 Pfizer
 - 7.5.1 Company profile
 - 7.5.2 Representative Pulmonary Hypertension Product
 - 7.5.3 Pulmonary Hypertension Sales, Revenue, Price and Gross Margin of Pfizer
- 7.6 United Therapeutics
 - 7.6.1 Company profile
 - 7.6.2 Representative Pulmonary Hypertension Product
 - 7.6.3 Pulmonary Hypertension Sales, Revenue, Price and Gross Margin of United Therapeutics
- 7.7 Gilead Sciences
 - 7.7.1 Company profile
 - 7.7.2 Representative Pulmonary Hypertension Product
 - 7.7.3 Pulmonary Hypertension Sales, Revenue, Price and Gross Margin of Gilead Sciences
- 7.8 Lung Biotechnology PBC

- 7.8.1 Company profile
- 7.8.2 Representative Pulmonary Hypertension Product
- 7.8.3 Pulmonary Hypertension Sales, Revenue, Price and Gross Margin of Lung Biotechnology PBC

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PULMONARY HYPERTENSION

- 8.1 Industry Chain of Pulmonary Hypertension
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PULMONARY HYPERTENSION

- 9.1 Cost Structure Analysis of Pulmonary Hypertension
- 9.2 Raw Materials Cost Analysis of Pulmonary Hypertension
- 9.3 Labor Cost Analysis of Pulmonary Hypertension
- 9.4 Manufacturing Expenses Analysis of Pulmonary Hypertension

CHAPTER 10 MARKETING STATUS ANALYSIS OF PULMONARY HYPERTENSION

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order:

Product name: Pulmonary Hypertension-EMEA Market Status and Trend Report 2013-2023
Product link: <https://marketpublishers.com/r/P5E0F7B9BF28EN.html>
Product ID: P5E0F7B9BF28EN
Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/P5E0F7B9BF28EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**